"People with the double diabetes phenotype may benefit from some of the medications that are currently approved for type 2 diabetes." That was the idea behind the new trial of semaglutide, the ingredient found in the weight-loss drug Ozempic and type 2 diabetes drug Wegovy
Warning signs requiring prompt medical attention include high fever, severe abdominal pain, bloody stools, or signs of allergic reaction

Theoretical risks are extrapolated from IGF-1 biology: Hypoglycemia : IGF-1 shares structural homology with insulin and can activate insulin receptors, particularly at high concentrations Growth factor signaling : Sustained IGF-1R activation carries theoretical oncogenic potential, as the IGF-1 axis promotes cell proliferation and survival Systemic effects : Reduced IGFBP binding means greater systemic exposure to active growth factor, potentially amplifying both therapeutic and adverse effects Organ-specific : Potential for cardiac hypertrophy and other tissue growth with chronic exposure MGF Side Effects# MGF safety data are limited to preclinical observations: Rapid clearance : The very short half-life limits systemic exposure, which may reduce off-target effects Local action : Endogenous MGF acts primarily as a local paracrine factor, suggesting that targeted administration may have a favorable safety profile No human data : Without clinical trials, the safety profile in humans remains undefined Proliferative concerns : As a satellite cell activator, theoretical concerns exist regarding uncontrolled proliferation, though preclinical data have not demonstrated this Dosing and Administration Comparison# IGF-1 LR3 Dosing# MGF Dosing# The short half-life of native MGF is a significant practical limitation

Practice Excellent Oral Hygiene- You know the drill: brush twice a day and make sure to floss and rinse with mouthwash to clear bacteria, plaque, and food particles
Atlantic salmon (Salmo salar) co-product-derived protein hydrolysates: A source of antidiabetic peptides
No, swollen lymph nodes (lymphadenopathy) are not listed as a recognised side effect in the UK regulatory data for GLP-1 receptor agonists